stockrowWhat it does
Guardant Health is a precision oncology company that sells blood and tissue tests used in cancer care. Its tests help clinicians choose treatments, look for cancer remaining after treatment, monitor for recurrence and screen for cancer. The company also sells testing and data services to biopharmaceutical companies developing cancer therapies.
A liquid biopsy analyzes material in a blood sample rather than requiring a new tissue biopsy. Guardant360 Liquid and Guardant360 CDx help identify tumor mutations that can inform treatment for patients with advanced cancer. Guardant360 Tissue profiles tumor tissue. Guardant Reveal uses blood to detect residual or recurring disease in early-stage colorectal, breast and lung cancers; it is also offered for monitoring treatment response in advanced solid tumors.
Shield is a blood test for colorectal cancer screening in average-risk adults age 45 and older. Patients taking Shield can also opt in to receive a multi-cancer detection report as part of a clinical data collection initiative. The company is working toward regulatory approval for Shield multi-cancer detection.
For drug developers, Guardant provides tests for clinical studies and the GuardantINFORM platform, which combines genomic data with clinical information and analytical tools. Its Smart Platform uses genomic, epigenomic and RNA-based data across its product portfolio. Helmy Eltoukhy and Amirali Talasaz are co-chief executive officers.
How it makes money
Guardant generates revenue from oncology tests, biopharmaceutical testing and data services, screening, and licensing and other activities. It reports one operating segment. Oncology tests are ordered for patients by clinicians, while biopharmaceutical customers use tests and data in research, clinical studies and companion diagnostic development. A companion diagnostic helps identify patients who may benefit from a particular therapy.
FY2025 revenue was $982.0 million; Q3 2026 revenue was $361 million.
Oncology was the largest revenue category in FY2025, at $683.6 million. Biopharma and data revenue was $210.1 million. The company’s clinical testing revenue depends on the number and mix of tests performed and the payments it expects to collect. Some patients can receive repeated tests during treatment or surveillance, but testing frequency depends on clinical use and coverage rather than a subscription contract.
Commercial and government payers reimburse eligible tests. Contracted commercial payers generally pay negotiated fees for covered uses, while non-contracted payers determine what they will reimburse and can adjust amounts. Guardant estimates oncology and screening revenue using expected collections; amounts collected above those estimates are recorded in later periods.
Shield’s average selling price was above $800 in Q3 2026. The company expects the average to decline somewhat as the mix of commercially insured patients increases, before potentially rising as a payment history develops. It had begun commercial-payer pricing discussions but had not reached pricing agreements. Medicare coverage and reimbursement terms vary by test and indication.
| Product or service | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Oncology | $683.6 million | 69.6% | 25.9% |
| Biopharma and data | $210.1 million | 21.4% | 18.3% |
| Screening | $79.7 million | 8.12% | 1,456.0% |
| Licensing and other | $8.6 million | 0.87% | −36.5% |
Customers and how it sells
Guardant sells clinical tests to oncologists, cancer centers and primary care physicians through its U.S. sales organization. Its commercial efforts also target community oncology practices, academic research institutions, health systems and physician networks. A separate business development team sells to biopharmaceutical companies in the United States and internationally, including for clinical-study enrollment and companion diagnostic development.
One customer accounted for 28.0% of FY2025 revenue. The company also depends on commercial insurers and government programs to cover and reimburse eligible tests. Shield meets Medicare coverage requirements for eligible colorectal cancer screening, and UnitedHealthcare coverage became effective in August 2026.
The United States generated $923.3 million, or 94.0%, of FY2025 revenue. International revenue was $58.7 million. Outside the United States, Guardant offers tests through contacts with insurers and hospitals, distributors and laboratory partners. Its partner laboratories include facilities in Spain, the United Kingdom and Italy. The company has also expanded commercialization into Asia, the Middle East and Africa, and its Guardant360 CDx test has regulatory approval and national reimbursement for certain uses in Japan.
| Region | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| United States | $923.3 million | 94.0% | 32.4% |
| International | $58.7 million | 5.98% | 40.3% |
Suppliers and costs
Guardant performs clinical, research-use and investigational tests at its Redwood City, California laboratory and clinical tests at a Long Island City, New York laboratory. Its California laboratories also support research and technology development. The Smart Platform uses common equipment, reagents, bioinformatics and staffing across products. The company invests in clinical studies, product development, laboratory capacity, sales and marketing.
Guardant fully implemented a lower-cost, higher-throughput Shield workflow in August 2026 following FDA approval. Shield cost per test fell from $410 in Q2 to $330 in Q3. The company expects further reductions from scale and automation at a new Palo Alto laboratory scheduled to go live in 2027. It targets $200 cost per test by the end of 2028.
Guardant expects operating expenses to increase as it invests in clinical studies, new products and commercial adoption. It also anticipates that capital spending requirements could increase if growing test demand requires additional laboratory capacity.
- Revenue$982.0M
- Cost of revenue−$349.0M
- Research and development−$364.2M
- Selling, general and administrative−$706.1M
- Operating income−$437.2M
Competitive position
Guardant competes with diagnostic companies that profile cancer genes using blood or tissue. In liquid biopsy for therapy selection, it names Foundation Medicine, Caris Life Sciences, Tempus AI, NeoGenomics, Exact Sciences, BillionToOne, Quest Diagnostics and Laboratory Corporation of America among its competitors.
In minimal residual disease detection, competitors include Natera, Tempus AI, Exact Sciences, Myriad Genetics, Caris, Foundation Medicine, BillionToOne, Personalis and Quest. In early screening, Guardant names GRAIL, Exact Sciences, Freenome, Natera and Delfi Diagnostics. Some customers are also developing their own tests, while sequencing-platform providers can sell technology to laboratories, researchers and biopharmaceutical companies.
Guardant identifies product price and performance, clinical evidence, turnaround time, commercial reach and payer contracts as competitive factors. Shield meets Medicare coverage requirements for eligible colorectal screening, and Guardant360 CDx has FDA approval for specified uses. The company has also accumulated testing data for its analytical platform.
Our reading: Regulatory approvals, coverage and clinical evidence provide a meaningful competitive foundation, but their value depends on the indication and the payer. Our reading: The shared platform and accumulated data can support product development across several uses, although competitors offer tests in many of the same markets.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Foundation Medicine, Inc. | Therapy selection and residual disease testing | Medium |
| Caris Life Sciences, Inc. | Therapy selection and residual disease testing | Medium |
| Tempus AI, Inc. | Therapy selection and residual disease testing | Medium |
| NeoGenomics, Inc. | Liquid biopsy for therapy selection | Medium |
| Exact Sciences Corporation | Therapy selection, residual disease testing and early screening | High |
| BillionToOne, Inc. | Therapy selection and residual disease testing | Medium |
| Quest Diagnostics, Inc. | Therapy selection and residual disease testing | Medium |
| Laboratory Corporation of America | Liquid biopsy for therapy selection | Medium |
Growth opportunities
Guardant is pursuing adoption across treatment selection, residual disease detection and screening. It plans to expand physician awareness, seek broader payer coverage and invest in clinical evidence. International growth efforts include distributor and laboratory partnerships, reimbursement applications and local laboratory capabilities.
Screening has expanded since Shield received Medicare coverage. Screening revenue was $79.7 million in FY2025, up from $5.1 million in FY2024. In Q3 2026, Shield revenue was $68 million and volume reached 83,000 tests. Guardant estimates that approximately 100 million people, or greater than 80% of the eligible U.S. screening population, will be covered for Shield as it enters 2027. Coverage does not by itself establish a payment rate for every payer.
The company is developing Shield for lung cancer screening and multi-cancer detection. It has launched Reveal Ultra to biopharmaceutical partners and plans a clinical launch before year-end 2026. Guardant has also submitted an FDA premarket approval application for Guardant360 Tissue and is developing additional applications for Guardant360 Liquid.
For full-year 2026, Guardant expects revenue of $1.36 to $1.37 billion and screening revenue of $233 to $238 million. It expects company-wide free cash flow breakeven by the end of 2027.
- $373.7MFY2021
- $449.5MFY2022
- $563.9MFY2023
- $739.0MFY2024
- $982.0MFY2025
- $1.4BFY2026 guidance
Structural risks
- Losses and funding: Guardant has incurred losses and negative operating cash flows since inception. It expects additional operating losses in the near future and may need additional financing if available resources and cash flows are insufficient.
- Coverage and payment: Revenue depends on payer coverage and reimbursement. Commercial payers can reduce reimbursement or seek to recover amounts previously paid, and coverage may be limited to particular indications.
- Adoption and clinical evidence: Growth depends on clinicians and biopharmaceutical companies adopting the tests. Product development can fail if a test does not perform as expected, lacks validation data or cannot demonstrate clinical utility.
- Regulation: New or significantly modified devices may require FDA clearance or approval. Reviews can be lengthy and costly, and approval is not assured; approved products also remain subject to regulatory conditions.
- Competition and intellectual property: Diagnostic companies and some customers are developing competing tests. It was reported on 5 November 2026 that a court ordered an ongoing 6% royalty on sales of 11 covered Guardant products and services through March 15, 2033.
Bottom line
Our reading
Guardant combines a cancer-testing laboratory business with screening and services for drug developers. Our reading: Its approvals, clinical data and shared platform support several routes to growth, while payer decisions and the pace of test adoption remain central to converting that opportunity into revenue. The company has grown sales but continues to incur losses; our reading is that the cost of expanding screening and developing new tests remains important alongside reimbursement progress.